Outcome of patients with advanced solitary fibrous tumors: the Centre Léon Bérard experience
1 Department of Medical Oncology, Centre Léon Bérard, 28 rue Laennec, 69008, Lyon, France
2 Department of Surgical Oncology, Centre Léon Bérard, 28 rue Laennec, 69008, Lyon, France
3 Department of Anatomopathology, Centre Léon Bérard, 28 rue Laennec, 69008, Lyon, France
4 Department of Medical Oncology, Centre Léon Bérard, Lyon, France
BMC Cancer 2013, 13:109 doi:10.1186/1471-2407-13-109Published: 11 March 2013
Solitary Fibrous Tumor is a rare type of soft tissue tumor of intermediate malignant potential which may recur or metastasize in 15-20% of cases. Data on the management of patients with advanced SFT is scarce: chemotherapy has been described as ineffective, while recent data suggests that anti-angiogenic therapies may be more efficient.
We conducted a retrospective study on patients treated for advanced SFT at a single institution: from January 1994 to December 2011, 30 patients were treated in the Centre Léon Bérard for an advanced SFT.
Twenty-three patients received cytotoxic chemotherapy as first-line therapy. Best responses were 2 (9%) partial responses, 13 (57%) stable diseases (SD) and 8 (35%) progressive diseases (PD). Median Progression Free Survival (PFS) was 5.2 (95% CI: 3.2-7.1) months and 9 patients were free of progression at 6 months. Ten patients received an anti-angiogenic treatment (sunitinib or pazopanib) as a 2nd, 3rd or 4th line. Best responses were 5 SD and 5 PD; median PFS was 5.1 months (95% CI 0.7-9.6). Four patients (36%) were progression-free for more than 6 months. Two patients receiving pazopanib were without progression at 6 and 8 months and two patients receiving sunitinib were free of progression at 30 months.
Response rate with standard chemotherapy was low and PFS appear similar between cytotoxic chemotherapy and anti-angiogenic agents.